Evidence map›Paper›PMID 23230288›Full record

ArticleInfection and immunity2013

Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection.

Sherry L Kurtz, Oded Foreman, Catharine M Bosio, Miriam R Anver, Karen L Elkins

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. The immune response toFrontiers in microbiology · 2025
    Review
  3. Article
  4. Deletion Mutants ofPathogens (Basel, Switzerland) · 2021
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Vaccine-Mediated Mechanisms ControllingPathogens (Basel, Switzerland) · 2020
    Article
  10. Article
  11. Guanylate-Binding Proteins Are Critical for Effective Control ofFrontiers in cellular and infection microbiology · 2020
    Article
  12. EarlyEvolutionary applications · 2019
    Article
  13. Infection and immunity · 2018
    Article
  14. Vaccine-Mediated Mechanisms Controlling Replication ofFrontiers in cellular and infection microbiology · 2018
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Sherry L KurtzLaboratory of Mycobacterial Diseases and Cellular Immunology, Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD, USA.
Oded Foreman
Catharine M Bosio
Miriam R Anver
Karen L Elkins
Center for Biologics Evaluation and Research · USFrederick National Laboratory for Cancer Research · USJackson Laboratory · US

Funding

Immunity to Pulmonary InfectionsZIAAI001013 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BOSIO, CATHARINE · 2009 to 2025
$18.9M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

We employed Francisella tularensis live vaccine strain (LVS) to study mechanisms of protective immunity against intracellular pathogens and, specifically, to understand protective correlates. One potential molecular correlate identified previously was interleukin-6 (IL-6), a cytokine with pleotropic roles in immunity, including influences on T and B cell functions. Given its role as an immune modulator and the correlation with successful anti-LVS vaccination, we examined the role IL-6 plays in the host response to LVS. IL-6-deficient (IL-6 knockout [KO]) mice infected with LVS intradermally or intranasally or anti-IL-6-treated mice, showed greatly reduced 50% lethal doses compared to wild-type (WT) mice. Increased susceptibility was not due to altered splenic immune cell populations during infection or decreased serum antibody production, as IL-6 KO mice had similar compositions of each compared to WT mice. Although LVS-infected IL-6 KO mice produced much less serum amyloid A and haptoglobin (two acute-phase proteins) than WT mice, there were no other obvious pathophysiological differences between LVS-infected WT and IL-6 KO mice. IL-6 KO or WT mice that survived primary LVS infection also survived a high-dose LVS secondary challenge. Using an in vitro overlay assay that measured T cell activation, cytokine production, and abilities of primed splenocytes to control intracellular LVS growth, we found that IL-6 KO total splenocytes or purified T cells were slightly defective in controlling intracellular LVS growth but were equivalent in cytokine production. Taken together, IL-6 is an integral part of a successful immune response to primary LVS infection, but its exact role in precipitating adaptive immunity remains elusive.

Indexed as

AnimalsBacterial VaccinesFrancisella tularensisHaptoglobinsInterleukin-6Lymphocyte ActivationMaleMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutSerum Amyloid A ProteinT-LymphocytesTularemiaVaccines, AttenuatedBacterial VaccinesHaptoglobinsInterleukin-6interleukin-6, mouseSerum Amyloid A ProteinVaccines, Attenuated

Identifiers

PMID23230288
PMCPMC3553820
OpenAlexW2109288121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.